{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116578","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.874057+00:00","generated_at":"2026-06-22T01:36:32.764118+00:00","sec_items":["2.03","1.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NRx Pharmaceuticals closes $11M unsecured debt financing from Streeterville Capital for Phase 3 trials","bullets":["Secured $11M unsecured note from Streeterville Capital; net proceeds ~$10M after $1M OID and fees.","Note bears 9% interest, 18-month maturity; monthly redemptions up to $1M starting May 2023.","Redemptions may be paid in cash or common stock at 85% of VWAP; Company must reserve 45M shares.","Proceeds will fund Phase 3 trial of NRX-101 for suicidal bipolar depression and PTSD.","Note includes participation right for Streeterville on future debt issuances and most-favored-nation clause."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116578","json":"https://secwatch.observer/filing/0001104659-22-116578.json","markdown":"https://secwatch.observer/filing/0001104659-22-116578.md","text":"https://secwatch.observer/filing/0001104659-22-116578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/0001104659-22-116578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/tm2230161d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:36:32.764118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f28e6e65dc063e495b157b7bfd40054603b6e611","claim":"NRX Pharmaceuticals, Inc. incurred loan of $11,020,000 million with Streeterville Capital, LLC at 9% interest rate maturing 18 months from the issuance date.","evidence_excerpt":"On November 4, 2022, NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and, pursuant to the SPA, issued to the Lender an unsecured promissory note with a face amount of $11,020,000 million (the “Note”) before an original issue discount of $1,000,000, which was deducted from the proceeds of the Note.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/0001104659-22-116578-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$11,020,000 million"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Rate","value":"9% interest rate"},{"label":"Maturity","value":"18 months from the issuance date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}